RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ALX Oncology Holdings - Stock

ALX Oncology Holdings P/S 2024

ALX Oncology Holdings P/S

0

Ticker

ALXO

ISIN

US00166B1052

WKN

A2P79Z

As of Jul 5, 2024, ALX Oncology Holdings's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The ALX Oncology Holdings P/S history

ALX Oncology Holdings Aktienanalyse

What does ALX Oncology Holdings do?

ALX Oncology Holdings Inc is a biopharmaceutical company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. The company was founded in 2015 and is headquartered in Burlingame, California. It is listed on the NASDAQ stock exchange under the ticker symbol "ALXO." History ALX Oncology Holdings Inc was founded by Therese S. Wagner, a respected oncologist with extensive experience in cancer research. The company began its activities with a strong vision focused on developing targeted and effective treatments for cancer patients. Business Model ALX Oncology Holdings Inc is working on the development of immunotherapy products based on two mechanisms of action - inhibition of the CD47 molecule and activation of the myeloid cells of the immune system. The goal is to eliminate cancer cells by enabling them to be recognized and attacked by the immune system. This business model has the potential to improve both the effectiveness and versatility of cancer treatment. Divisions ALX Oncology Holdings Inc operates in several areas, including: Main products: • ALX148 - A monoclonal antibody that acts as a CD47 inhibitor • ALX148-Bispecifics - Two binding domains that contribute to the activation of the myeloid cells of the immune system In addition, ALX Oncology Holdings Inc collaborates with various partners to develop new drugs and therapies. These partnerships include both academic institutions and pharmaceutical companies. Products ALX148 is the flagship product of ALX Oncology. It is a monoclonal antibody that inhibits the CD47 molecule found on the surface of cancer cells, preventing their recognition by the immune system. By inhibiting CD47, the immune system can recognize and destroy cancer cells. ALX148-Bispecifics are antibody-drug conjugates (ADC) and bispecific antibodies (BsAb) that have been developed to activate the myeloid cells in the immune system by combining CD47 inhibitory capabilities with the activation of macrophage-associated ligands (CD40 and CD80). This results in a stronger immune response to cancer cells, leading to their destruction. Summary ALX Oncology Holdings Inc is a biotechnology company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. Their products, ALX148 and ALX148-Bispecifics, inhibit the CD47 molecule and activate the immune system to fight cancer cells. The company collaborates with various partners and has the potential to provide new hope for people with cancer. ALX Oncology Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding ALX Oncology Holdings's P/S Ratio

ALX Oncology Holdings's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing ALX Oncology Holdings's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating ALX Oncology Holdings's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in ALX Oncology Holdings’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about ALX Oncology Holdings stock

What is the price-to-earnings ratio of ALX Oncology Holdings?

The price-earnings ratio of ALX Oncology Holdings is currently 0.

How has the price-earnings ratio of ALX Oncology Holdings changed compared to last year?

The price-to-earnings ratio of ALX Oncology Holdings has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of ALX Oncology Holdings high compared to other companies?

Yes, the price-to-earnings ratio of ALX Oncology Holdings is high compared to other companies.

How does an increase in the price-earnings ratio of ALX Oncology Holdings affect the company?

An increase in the price-earnings ratio of ALX Oncology Holdings would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of ALX Oncology Holdings affect the company?

A decrease in the price-earnings ratio of ALX Oncology Holdings would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of ALX Oncology Holdings?

Some factors that influence the price-earnings ratio of ALX Oncology Holdings are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does ALX Oncology Holdings pay?

Over the past 12 months, ALX Oncology Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ALX Oncology Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of ALX Oncology Holdings?

The current dividend yield of ALX Oncology Holdings is .

When does ALX Oncology Holdings pay dividends?

ALX Oncology Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ALX Oncology Holdings?

ALX Oncology Holdings paid dividends every year for the past 0 years.

What is the dividend of ALX Oncology Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ALX Oncology Holdings located?

ALX Oncology Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von ALX Oncology Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ALX Oncology Holdings from 7/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/5/2024.

When did ALX Oncology Holdings pay the last dividend?

The last dividend was paid out on 7/5/2024.

What was the dividend of ALX Oncology Holdings in the year 2023?

In the year 2023, ALX Oncology Holdings distributed 0 USD as dividends.

In which currency does ALX Oncology Holdings pay out the dividend?

The dividends of ALX Oncology Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ALX Oncology Holdings

Our stock analysis for ALX Oncology Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ALX Oncology Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.